Cell Therapy Catapult

Cell Therapy Catapult

The Cell Therapy Catapult is to build its £55m state-of-the-art manufacturing centre at the Stevenage Bioscience Catalyst and is expected to create up to 150 jobs.  

World-leading innovation requires dedication, rigorous development and a team of people who believe that life-changing therapies should be accessible.

Through science and industry the Cell Therapy Catapult’s expertise in cell and gene therapies will one day provide better treatments that will ease suffering and improve quality of life, whilst building a global industry the UK can be truly proud of.

Business Secretary Vince Cable, said: “This therapy is at the very cutting edge of medical research, and is using our own cells in the fight against life threatening diseases including cancer.

“This state-of-the-art facility in Stevenage will ensure Britain can be a real leader in this industry. Supporting British scientists is crucial for our long term economic growth.” 

The Cell Therapy Manufacturing Centre, which is expected to open in 2017, will be used for manufacture of late phase clinical trial and commercial supply of advanced therapeutic medicinal products including cell and gene therapies. 

Keith Thompson, CEO of the Cell Therapy Catapult, said: “The centre will support global scientific and medical communities in their research into products that have the potential to address many unmet medical needs.”  

Martino Picardo, CEO of the Stevenage Bioscience Catalyst, said: “Companies coming to the Cell Therapy Catapult’s Manufacturing Centre will also be able to access expertise, networks and scientific facilities traditionally associated with multinational pharmaceutical companies.” 

Iain Gray, Chief Executive of Innovate UK, said: “This is an important next step in the establishment of the UK as a global manufacturing centre for the cell therapy industry."

The Cell Therapy Catapult supports the cell and gene therapy industry to create health and wealth from the UK’s outstanding research and make the UK the most compelling and logical choice for our international partners.

Funding Partners: